AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 13 592 GBX 0.58% Market Closed
Market Cap: 210.8B GBX

AstraZeneca PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AstraZeneca PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
AstraZeneca PLC
LSE:AZN
Operating Income
$14.2B
CAGR 3-Years
23%
CAGR 5-Years
29%
CAGR 10-Years
14%
GlaxoSmithKline PLC
LSE:GSK
Operating Income
£8.4B
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
5%
Verona Pharma PLC
NASDAQ:VRNA
Operating Income
-$56m
CAGR 3-Years
6%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Operating Income
$296m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Operating Income
$602m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
5%
Allergy Therapeutics PLC
LSE:AGY
Operating Income
-£28.3m
CAGR 3-Years
-87%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

AstraZeneca PLC
Glance View

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
HIDDEN
Show

See Also

What is AstraZeneca PLC's Operating Income?
Operating Income
14.2B USD

Based on the financial report for Sep 30, 2025, AstraZeneca PLC's Operating Income amounts to 14.2B USD.

What is AstraZeneca PLC's Operating Income growth rate?
Operating Income CAGR 10Y
14%

Over the last year, the Operating Income growth was 26%. The average annual Operating Income growth rates for AstraZeneca PLC have been 23% over the past three years , 29% over the past five years , and 14% over the past ten years .

Back to Top